The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on the latest advancements and new approaches in cancer research and was held virtually this year due to the COVID-19 pandemic Janssen highlights its oncology portfolio, Merck & Pfizer demonstrated the potential of Bavencio in GTT while AstraZeneca showcased […]Read More
Shots: The P-II OPTIC study involves assessing three initial doses of Iclusig (15/30/45 mg) in 283 patients with CML in CF, or who had documented history of the presence of the T315I mutation after receiving any number of previous TKIs With an average follow-up of~ 21 mos., the interim analysis showed that maximum BCR- ABL1 […]Read More
Shots: The P-Ib/II CARTITUDE-1 study involves assessing JNJ-4528 in 29 heavily pretreated patients with r/r MM. The P-Ib results will be shared at ASCO The P-Ib/II study results: 100% ORR with 97% good PR and 3% PR; patients achieving stringent CR @median of 11.5mos (86%), PFS at 9mos (86%); median time to first response was […]Read More
Shots::stohShots: The P-II CITYSCAPE study involves assessing of tiragolumab+ Tecentriq (atezolizumab) vs Tecentriq + PBO to in 135 patients with 1L PD-L1-positive NSCLC. The full results of the study will be presented at ASCO20 Virtual Scientific Program The P-II study results: met its co-1EPs in IIT population, ORR (31.3% vs16.2%), mPFS (5.4 vs 3.6mos.), @exploratory […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
